Detalles de la búsqueda
1.
Efficacy and immunogenicity following dengue virus-1 human challenge after a tetravalent prime-boost dengue vaccine regimen: an open-label, phase 1 trial.
Lancet Infect Dis;
2024 Apr 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-38679035
2.
Diverse array of neutralizing antibodies elicited upon Spike Ferritin Nanoparticle vaccination in rhesus macaques.
Nat Commun;
15(1): 200, 2024 Jan 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-38172512
3.
Antibody targeting of conserved sites of vulnerability on the SARS-CoV-2 spike receptor-binding domain.
Structure;
32(2): 131-147.e7, 2024 Feb 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-38157856
4.
Reduced maternal immunity and vertical transfer of immunity against SARS-CoV-2 variants of concern with COVID-19 exposure or initial vaccination in pregnancy.
Front Immunol;
14: 1216410, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37753075
5.
Zika-specific neutralizing antibodies targeting inter-dimer envelope epitopes.
Cell Rep;
42(8): 112942, 2023 08 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-37561630
6.
Targeting the Spike Receptor Binding Domain Class V Cryptic Epitope by an Antibody with Pan-Sarbecovirus Activity.
J Virol;
97(7): e0159622, 2023 07 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-37395646
7.
Humoral immune responses associated with control of SARS-CoV-2 breakthrough infections in a vaccinated US military population.
EBioMedicine;
94: 104683, 2023 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-37413891
8.
Impact of prior dengue virus infection on Zika virus infection during pregnancy in marmosets.
Sci Transl Med;
15(699): eabq6517, 2023 06 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-37285402
9.
Safety and immunogenicity of a purified inactivated Zika virus vaccine candidate in adults primed with a Japanese encephalitis virus or yellow fever virus vaccine in the USA: a phase 1, randomised, double-blind, placebo-controlled clinical trial.
Lancet Infect Dis;
23(10): 1175-1185, 2023 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-37390836
10.
Convalescent human IgG, but not IgM, from COVID-19 survivors confers dose-dependent protection against SARS-CoV-2 replication and disease in hamsters.
Front Immunol;
14: 1138629, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37026013
11.
SARS-CoV-2 spike-ferritin-nanoparticle adjuvanted with ALFQ induces long-lived plasma cells and cross-neutralizing antibodies.
NPJ Vaccines;
8(1): 43, 2023 Mar 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-36934088
12.
Blocking NS3-NS4B interaction inhibits dengue virus in non-human primates.
Nature;
615(7953): 678-686, 2023 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36922586
13.
Shark nanobodies with potent SARS-CoV-2 neutralizing activity and broad sarbecovirus reactivity.
Nat Commun;
14(1): 580, 2023 02 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36737435
14.
Protection against SARS-CoV-2 Omicron BA.1 variant challenge in macaques by prime-boost vaccination with Ad26.COV2.S and SpFN.
Sci Adv;
8(47): eade4433, 2022 Nov 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-36417525
15.
Coronavirus Antibody Responses before COVID-19 Pandemic, Africa and Thailand.
Emerg Infect Dis;
28(11): 2214-2225, 2022 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-36220131
16.
Beneath the surface: Amino acid variation underlying two decades of dengue virus antigenic dynamics in Bangkok, Thailand.
PLoS Pathog;
18(5): e1010500, 2022 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-35500035
17.
Enhanced Immunogenicity of Inactivated Dengue Vaccines by Novel Polysaccharide-Based Adjuvants in Mice.
Microorganisms;
10(5)2022 May 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-35630476
18.
A SARS-CoV-2 Spike Ferritin Nanoparticle Vaccine Is Protective and Promotes a Strong Immunological Response in the Cynomolgus Macaque Coronavirus Disease 2019 (COVID-19) Model.
Vaccines (Basel);
10(5)2022 May 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-35632473
19.
The seroepidemiology of dengue in a US military population based in Puerto Rico during the early phase of the Zika pandemic.
PLoS Negl Trop Dis;
16(1): e0009986, 2022 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35061659
20.
Unglycosylated Soluble SARS-CoV-2 Receptor Binding Domain (RBD) Produced in E. coli Combined with the Army Liposomal Formulation Containing QS21 (ALFQ) Elicits Neutralizing Antibodies against Mismatched Variants.
Vaccines (Basel);
11(1)2022 Dec 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-36679887